Gout is the most common inflammatory arthritis which affects nearly 2% of the total population.[1,2] The prevalence of gout has been increasing in many countries including the United States and China over the past decades.[3–5] Febuxostat is a novel xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. Here, XDH is linked to hyperuricemia.